Paper Details

  1. Home
  2. Paper Details

Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.

Author: , AlmukhtarTalat, BhoradeAnjali, BresslerNeil M, BresslerSusan B, GlassmanAdam R, HuangSuber S, JampolLee M, KimJudy E, MeliaMichele

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This research examines the potential risks of intravitreous anti-vascular endothelial growth factor (VEGF) injections for retinal disease. While VEGF inhibitors are widely used, the study explores concerns about sustained elevation of intraocular pressure (IOP) and potential glaucoma risk.
Paper Details　
Original Abstract of the Article :
For the management of retinal disease, the use of intravitreous injections of anti-vascular endothelial growth factor has increased. Recent reports have suggested that this therapy may cause sustained elevation of intraocular pressure (IOP) and may potentially increase the risk of glaucoma for patie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25719991

データ提供：米国国立医学図書館（NLM）

Intravitreous Ranibizumab: A New Treatment for Diabetic Macular Edema?

Diabetic macular edema, a condition that can obscure vision like a blinding sandstorm, is a significant challenge for those living with diabetes. This research explores the potential of intravitreous injections of ranibizumab, an anti-vascular endothelial growth factor, to combat this debilitating condition. However, the study raises concerns about a potential side effect of this treatment: sustained elevation of intraocular pressure (IOP).

Navigating the Sands of IOP Risk

The research, like a desert explorer carefully navigating treacherous terrain, investigates the link between ranibizumab injections and the risk of increased IOP. The authors aim to provide clinicians with valuable insights into the potential risks and benefits of this treatment, enabling them to make informed decisions about patient care.

A Balancing Act for Diabetic Patients

The study highlights the delicate balance that must be struck when considering treatment options for diabetic macular edema. While ranibizumab offers potential benefits in managing the condition, the risk of IOP elevation must be carefully weighed and monitored.

Dr.Camel's Conclusion

This research underscores the need for careful consideration and ongoing monitoring when using novel treatments. The potential benefits of ranibizumab must be balanced against the risk of IOP elevation, requiring a thorough understanding of both sides of the equation to ensure the best possible outcomes for patients.
Date :
  1. Date Completed 2015-08-14
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

25719991

DOI: Digital Object Identifier

NIHMS676945

Related Literature

Article Analysis
・Effective treatment of glaucoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.